Antares Pharma Inc
F:MJC
Antares Pharma Inc
Inventory
Antares Pharma Inc
Inventory Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Inventory | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
A
|
Antares Pharma Inc
F:MJC
|
Inventory
$11.5m
|
CAGR 3-Years
0%
|
CAGR 5-Years
17%
|
CAGR 10-Years
N/A
|
|
|
Johnson & Johnson
NYSE:JNJ
|
Inventory
$14.2B
|
CAGR 3-Years
4%
|
CAGR 5-Years
9%
|
CAGR 10-Years
6%
|
|
|
Bristol-Myers Squibb Co
NYSE:BMY
|
Inventory
$2.7B
|
CAGR 3-Years
5%
|
CAGR 5-Years
5%
|
CAGR 10-Years
8%
|
|
|
Pfizer Inc
NYSE:PFE
|
Inventory
$10.7B
|
CAGR 3-Years
6%
|
CAGR 5-Years
6%
|
CAGR 10-Years
4%
|
|
|
Merck & Co Inc
NYSE:MRK
|
Inventory
$6.7B
|
CAGR 3-Years
4%
|
CAGR 5-Years
1%
|
CAGR 10-Years
4%
|
|
|
Eli Lilly and Co
NYSE:LLY
|
Inventory
$13.7B
|
CAGR 3-Years
47%
|
CAGR 5-Years
28%
|
CAGR 10-Years
15%
|
|
Antares Pharma Inc
Glance View
Antares Pharma, Inc. is a specialty pharmaceutical company, which engages in the development and commercialization of pharmaceutical products and technologies in targeted therapeutic areas. The company is headquartered in Ewing, New Jersey and currently employs 201 full-time employees. The firm is focused on the development and commercialization of pharmaceutical products and technologies. The firm develops, manufactures, and commercialize, for itself or with partners, therapeutic products using its drug delivery systems. The firm products include XYOSTED, NOCDURNA, Epinephrine Injection USP, Sumatriptan Injection USP, Makena and Teriparatide Injection. Its XYOSTED injection product for subcutaneous administration of testosterone replacement therapy (TRT) in adult males for conditions associated with a deficiency or absence of endogenous testosterone. NOCDURNA is used for the treatment of nocturia due to nocturnal polyuria (NP) in adults who awaken at least two times per night to urinate. Its Epinephrine Injection USP products is indicated for emergency treatment of severe allergic reactions including those that are life threatening (anaphylaxis) in adults and certain pediatric patients.
See Also
What is Antares Pharma Inc's Inventory?
Inventory
11.5m
USD
Based on the financial report for Dec 31, 2021, Antares Pharma Inc's Inventory amounts to 11.5m USD.
What is Antares Pharma Inc's Inventory growth rate?
Inventory CAGR 5Y
17%
Over the last year, the Inventory growth was -37%.
